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Alterations to brain homeostasis during development are reﬂected in the neurochemical proﬁle deter-
mined noninvasively by 1H magnetic resonance spectroscopy. We determined longitudinal biochemical
modiﬁcations in the cortex, hippocampus, and striatum of C57BL/6 mice aged between 3 and 24 months .
The regional neurochemical proﬁle evolution indicated that aging induces general modiﬁcations of
neurotransmission processes (reduced GABA and glutamate), primary energy metabolism (altered
glucose, alanine, and lactate) and turnover of lipid membranes (modiﬁcation of choline-containing
compounds and phosphorylethanolamine), which are all probably involved in the frequently observed
age-related cognitive decline. Interestingly, the neurochemical proﬁle was different in male and female
mice, particularly in the levels of taurine that may be under the control of estrogen receptors. These
neurochemical proﬁles constitute the basal concentrations in cortex, hippocampus, and striatum of
healthy aging male and female mice.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Aging is accompanied by various cellular challenges in the brain,
which lead to homeostatic alterations and ultimately result in the
reduction of neuronal function and cognitive performance (Bizon
et al., 2012). Although aging mechanisms are not fully under-
stood, age-dependent brain modiﬁcations are likely reﬂected in
alterations of the regional distribution of levels of neurochemicals.
The concentration patterns of these compounds composing the
neurochemical proﬁle vary with cellular composition and function
of the tissue, thus reﬂecting the structural differentiation of cere-
bral networks in a region-speciﬁc manner, and are affected by
modiﬁcation of functional states and by neuropathologies
(reviewed in Duarte et al., 2012a). This supports the use of the
neurochemical proﬁle as region- and time-speciﬁc biomarker and,
indeed, its noninvasive detection by magnetic resonance spec-
troscopy (MRS) has emerged as an important research tool in
translational neuroscience. Neurochemical proﬁling has thus been
successfully used to reliably probe brain biochemical modiﬁcations
upon disease and/or treatment monitoring in mice (Berthet et al.,nal and Metabolic Imaging,
(Bâtiment CH), CH-1015 Lau-
).
ll rights reserved.2011; Duarte et al., 2012b; Zacharoff et al. 2012), rats (Duarte
et al., 2009; Rao et al., 2011), or humans (Bustillo et al., 2009;
Seaquist et al., 2005). Each neuropathology has different etiology,
is region speciﬁc and occurs with most prominence at a particular
age range. For example, while schizophrenia is a neurodevelopment
disorder, other nowadays-common disorders like Alzheimer’s dis-
ease or Parkinson’s diseasemostly affect themiddle aged and rapidly
increasing elderly population. In humans, studies in elderly subjects
were performed at low-magnetic ﬁeld and focused on the most
prominent resonances in 1H nuclear magnetic resonance (NMR)
spectra rather than determining an extensive neurochemical proﬁle
(Chang et al., 1996; Gruber et al., 2008; Schuff et al., 1999, 2001). In
experimental animal models, the extended neurochemical proﬁle
detected in vivo by high-ﬁeld 1HMRS has been studied from birth to
adulthood, disregarding the aging brain. Contributing for this is the
fact that genetic manipulations in rodents allow to reach disease
phenotypes at early age. Therefore, age-dependent modiﬁcations to
the neurochemical proﬁle remain to be investigated.
Most magnetic resonance scanners available for clinical routine
are operating at low-magnetic ﬁeld. Therefore, the extensive
neurochemical proﬁle observed in animal studies is not directly
applicable to the clinical environment. Nevertheless, even at 1.5 T,
several metabolites are distinguishable in 1H MRS at short echo time
(discussed in Duarte et al., 2012a). Then, analysis with appropriate
algorithms provides measurements of several compounds such as
Fig. 1. Localized 1H NMR spectra from the hippocampus (A), cortex (B) and striatum (C) of a 2-year-old female mouse acquired with SPECIAL at 14.1 T. Spectra were processed with
Gaussian multiplication (gf ¼ 0.08, gfs ¼ 0.02), Fourier transformation and phase correction. Residual water signal removal or baseline correction was not applied. On the right of each
spectrum, a representative fast-spin-echo image was used to show typical location of the volume of interest for spectroscopy. Metabolites in the spectra are assigned as follows: lactate (1),
alanine (2), g-aminobutyrate or GABA (3), N-acetylaspartate (4), N-acetylaspartylglutamate (5), glutamate (6), glutamine (7), glutathione (8), aspartate (9), phosphocreatine (10), creatine
(11), phosphorylcholine (12), glycerylphosphorylcholine (13), taurine (14), scyllo-inositol (15), myo-inositol (16), glycine (17), ascorbate (18), glucose (19), phosphorylethanolamine (20).
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compounds, and glutamate plus glutamine (the so called “Glx”). In a
clinical 3.0 T system, Mekle et al. (2009) achieved spectral resolution
sufﬁcient to quantify a neurochemical proﬁle composed 14 metabo-
lites. The same neurochemical proﬁle was determined with only
3 minutes of scan time at 7.0 T (Gambarota et al., 2009; Mekle et al.,
2009; Tkác et al., 2009) and at 9.4 T (Deelchand et al., 2010). This
means that, at high ﬁeld, the variety of neurochemicals detected in
the human brain increasingly resemble those in rodents, that is, 20
metabolites. MRS is therefore a reliable method for diagnosing
neurologic disorders and monitoring therapy outcomes, allowing
early disease detection and preventive approaches. Furthermore,
because the exact same tool can be applied noninvasively to rodents,
high-ﬁeld 1H MRS in animal models with speciﬁc neuropathological
phenotypes became a method of choice for translational research
aiming at understanding biochemical mechanisms of disease devel-
opment and progression. The aim of this study was to investigate the
longitudinal modiﬁcation of the neurochemical proﬁle in vivo in the
cortex, hippocampus, and striatum of C57BL/6 mice by 1H MRS at
14.1 T. The analysis of these 3 brain areas aimed at depicting a di-
versity of brain functions and targets of neurologic disorders.
2. Methods
2.1. Animals
All experiments were conducted under approval of the local
ethics committee in C57BL/6 mice that were born in the localanimal facility. Mice were housed on a 12-hour light-dark cycle
with room temperature at 22 C and humidity at 50%e60%. Regular
chow and tap water were provided ad libitum. The neurochemical
proﬁles of hippocampus, cortex, and striatum were determined
longitudinally in 36 mice (19 males and 17 females) at the age of 3,
6, 12, 18, and 24months. All scans were performed during the light-
cycle under anesthesia of 1%e1.5% isoﬂurane in oxygen gas and the
duration of each NMR scanning session was restricted to a
maximum of 120 minutes (Kulak et al., 2010).
2.2. MRS
Mice were ﬁxed in a mouse holder with a bite bar and 2 ear
inserts (RAPID Biomedical GmbH, Rimpar, Germany). Body tem-
perature was maintained at 37 C by warm water circulation. All
experiments were carried out in a horizontal 14.1 T/26 cm magnet
(Magnex Scientiﬁc, Abingdon, UK), with a 12 cm inner-diameter
gradient (400 mT/m in 200 ms, minimized eddy currents), inter-
faced with a DirectDrive console (Agilent Technologies, Palo Alto,
CA, USA). Radio frequency transmission and receptionwas achieved
with a home-built quadrature surface coil composed of 2 geomet-
rically decoupled single-turn loops of 12 mm inner diameter
resonating at 600 MHz. The mouse brain was positioned in the
isocenter of the magnet and located with fast-spin-echo images
with repetition time of 4 seconds, echo time of 52 ms, and echo
train length of 8. Field homogeneity in the region of interest was
achieved with FAST(EST)MAP (Gruetter, 1993; Gruetter and Tkác,
2000). Volumes of interest were placed in the hippocampus
Fig. 2. Age-dependent modiﬁcation of concentration of compounds that compose the neurochemical proﬁle in the cortex (triangles), striatum (circles), and hippocampus (squares)
of C57BL/6 mice. Neurochemical modiﬁcations were measured from 1H NMR spectra acquired in vivo longitudinally from the 3 regions of the mouse brain aged 3, 6, 12, 18, and 24-
month-old. x, þ, and # represent signiﬁcant differences at p < 0.01 compared with 3 months for the hippocampus, cortex, and striatum, respectively. Double symbols depict p <
0.001.
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(2.0  1.8  2.0 mm3) of the C57BL/6 mice. NMR spectra were ac-
quired using SPECIAL (Mlynárik et al., 2006) with echo time of
2.8 ms, repetition time of 4 seconds, and typically with 320e400
scans.
Metabolite concentrations were determined using the linear
combination analysis method LCModel (Stephen Provencher Inc,
Oakville, Ontario, Canada), including a macromolecule (Mac)
spectrum in the database (Mlynárik et al., 2006; Duarte et al.,
2012b). The unsuppressed water signal measured from the same
volumes of interest was used as an internal reference for the ab-
solute quantiﬁcation of metabolites. The following 20 metabolites
were included in the LCModel analysis: alanine (Ala), ascorbate
(Asc), aspartate (Asp), creatine (Cre), g-aminobutyrate (GABA),
glutamine (Gln), glutamate (Glu), glutathione (GSH), glycine (Gly),
glycerophosphorylcholine (GPC), glucose (Glc), lactate (Lac),
myo-inositol (Ins), N-acetylaspartate (NAA), N-acetylaspartylgluta-
mate (NAAG), phosphorylethanolamine (PE), phosphorylcholine
(PCho), phosphocreatine (PCre), scyllo-inositol (scyllo), and taurine(Tau). The CraméreRao lower bound (CRLB) was provided by the
LCModel as a measure of the reliability of the apparent metabolite
concentration quantiﬁcation. In most measured spectra, the pre-
sent analysis was not able to reliably discern phosphorylcholine
from glycerophosphorylcholine. Therefore, their sum was quanti-
ﬁed as total choline-containing compounds (GPC þ PCho or tCho).
Because the relative content of creatine (Cre) and phosphocreatine
(PCre) may depend on the energy status of the tissue, the total
creatine concentration (Cre þ PCre or tCre) was reported as a
constitutive metabolic pool of the tissue. The ratios of PCre to Cre,
Gln to Glu, and Asp to Glu were also analyzed.
2.3. Water content
Tissue water content was used for absolute quantiﬁcation of
neurochemicals. Thus, in another set of mice, water content varia-
tions during aging were determined in the cortex, hippocampus,
and striatum at the age of 6, 12, and 24 months by the difference in
wet and dry tissue weights. After decapitation under isoﬂurane
Fig. 3. Relevant metabolite ratios are modiﬁed upon aging in the mouse brain.
Hippocampus, cortex, and striatum are represented by squares, triangles, and circles,
respectively; x, þ, and # represent signiﬁcant differences at p < 0.01 compared with
mice aged 3 months for the hippocampus, cortex, and striatum, respectively. Double
symbols depict p < 0.001.
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65 C until dry weight did not vary. After desiccation, water content
was calculated from the wet-dry weight difference. For younger
animals, water content measurements were available from previ-
ous reports (Agrawal et al., 1968; Cohadon and Desbordes, 1986;
Kulak et al., 2010; Larvaron et al., 2006).
2.4. Statistical analysis
Results are presented as mean  standard error of the mean.
Data were analyzed in IBM SPSS 20 (IBM Corp, Armonk, NY, USA)
with multivariate analysis of variance (MANOVA), performed with
respect to metabolite in the neurochemical proﬁle, brain region
and mouse gender, having age as a repeated factor. Then,
metabolite-speciﬁc age effects with conﬁdence level above 90%
(p < 0.1) were followed up with paired t tests, for which signiﬁ-
cance level was set at p < 0.01. Correlation between quantiﬁed
metabolites was tested with the Pearson correlation analysis to all
measured datasets, that is, including 3 brain regions, 5 ages, and
both genders.
3. Results
3.1. Quantiﬁcation of neurochemicals
Typical 1H NMR spectra from the rat brain in vivo exhibited
excellent metabolite line widths (Fig. 1). In particular, for spectra
acquired in the hippocampus, cortex, and striatum, respectively,
average line width at half maximum was 16.1  0.4 Hz, 19.7 
0.6 Hz, and 16.3  0.5 Hz, as estimated by the LCModel. Water was
consistently well suppressed and signal to noise was 21.0 0.5, 18.4
 0.4, and 16.3  0.3 in spectra from the hippocampus, cortex and
striatum. This allowed determining a neurochemical proﬁle of 19
metabolites that were quantiﬁed with CRLB generally below 25%.
CRLB for glucose and phosphorylethanolaminewere below 30% and
for scyllo-inositol were lower than 40%.
In this study, water content was quantiﬁed by desiccation for the
hippocampus, cortex, and striatum and used to determine absolute
metabolite concentrations. Water fraction did not differ within
experimental accuracy between the 3 measured regions of the
mouse brain, but was substantially reduced with aging. At the ageof 6 and 12 months, water content was 79  1% (n ¼ 4) and 79  1%
(n¼ 6), respectively, and reduced to 751% at the age of 24months
(n ¼ 9, p < 0.01 vs. 6 and 12 months). Average reported water
content at the age of 1 month was 80  1% (Agrawal et al., 1968;
Cohadon and Desbordes, 1986; Kulak et al., 2010; Larvaron et al.,
2006). Water content at these ages and interpolated at the age of
3 and 18 months was used to estimate absolute concentration of
metabolites in the brain.
3.2. Regional variation of metabolite concentrations
Regional speciﬁcity of spectral lines was directly evident from
the relative height of NAA, creatine, and taurine peaks in 1H NMR
spectra acquired in vivo in the cortex, striatum, and hippocampus of
adult mice (Fig. 1). The concentration of metabolites in the neuro-
chemical proﬁle across the brain regions varied between the age of
3 and 24 months (Fig. 2). Analysis of these results with MANOVA
clearly indicated that the neurochemical proﬁle is region speciﬁc
(Supplementary Table 1). Although only glucose was not statisti-
cally different in the 3 brain regions (F ¼ 1.431, p > 0.05), the age
evolution of metabolite concentrations was generally similar,
except for taurine, NAAG, and glycine that displayed signiﬁcant
region-age or region-age-gender interactions (Supplementary
Table 1).
3.3. Aging-dependent neurochemical modiﬁcations
The most prominent age-dependent neurochemical modiﬁca-
tions were in the concentration of metabolites involved in neuro-
transmission, energy metabolism, or maintenance of cellular
membranes (Fig. 2, Supplementary Tables 1 and 2). In particular, the
main excitatory and inhibitory neurotransmitters, glutamate and
GABA, were substantially reduced upon aging in the measured re-
gions (p < 0.001). Compared with young adult mice, that is, at the
age of 3 months, glutamate was reduced in the hippocampus, cor-
tex, and striatum of 2-year-oldmice by 131%,112%, and 17 2%
(p < 0.001) and GABAwas decreased by 10  3%, 19  6%, and 27 
3% (p < 0.001), respectively. Aspartate was also reduced (p < 0.05)
in the cortex (25  5%, 24 vs. 3 months) and hippocampus (19 
5%, 24 vs. 3 months) but not in striatum (þ44  15%, 24 vs.
3 months).
This modiﬁcation in levels of neuroactive-amino acids was
accompanied by a reduction in the concentration of glucose (p <
0.01, 24 vs. 3 months:19.6 6.3%,20.6 8.4%, and44.0 5.9%
in the hippocampus, cortex, and striatum, respectively), as well as
in lactate (p < 0.001) and/or alanine (p < 0.001).
Compounds involved in lipid metabolism and plasma mem-
brane turnover were modiﬁed in the 3 measured regions. Namely,
while aging was associated with a reduction in the concentration of
phosphorylethanolamine in the hippocampus, cortex, and striatum
(p < 0.001; 34  5%, 30  7%, and 36  6% for 24 vs. 3 months,
respectively), choline-containing compounds increased over the 2
years (p < 0.01; 24 vs. 3 months: þ12  2%, þ14  3%, and þ2  2%
in the hippocampus, cortex, and striatum, respectively).
The content of myo-inositol was reduced after the age of 3
months and displayed a tendency to increase in brain regions of
2-year-old mice (p < 0.01), while the other isomer of inositol pre-
sent in the brain in important amounts, scyllo-inositol, increased
with age (p < 0.05). Total creatine, which is frequently taken as a
reference compound in MRS studies, was found to decrease with
age in the hippocampus, cortex, and striatum by 4  1%, 5  2%,
and7 2%, respectively (24 vs. 3 months, p< 0.05). In adult mice,
taurine concentration only varied with age in the striatum (13 
4% for 24 vs. 3 months, p < 0.05). Glutathione showed an evolving
pattern similar to that of taurine, being modiﬁed in the striatum
Fig. 4. Correlation between metabolite concentrations and/or ratios that are putative markers of speciﬁc cell populations and metabolic states. (A) Pearson correlation coefﬁcients
(r) depict linear dependence between metabolite concentrations and/or metabolite ratios within the measured neurochemical proﬁle. (B) Demonstrates the correlation of regional
glutamate and NAA concentrations across mouse age and gender. The resulting slope in linear ﬁt is represented by the gray line (R2 ¼ 0.859). (C) Glutamine versus myo-inositol
concentrations. Dashed line represents the linear relation between glutamine and myo-inositol in data from the cortex (R2 ¼ 0.659). (D) Relation between lactate concentration
and metabolite ratios Gln to Glu (R2 ¼ 0.524), Asp to Glu (R2 ¼ 0.472), and PCre to Cre (R2 ¼ 0.263). (BeD) Data from hippocampus, striatum, and cortex are shown in circles, squares
and triangles, respectively. Data from female mice are colored in red, while black depicts male mice. Abbreviation: NAA, N-acetylaspartate.
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measured regions.
Importantmetabolite ratios were determined and also displayed
regional speciﬁc and/or age-dependent modiﬁcation: Gln to Glu,
Asp to Glu, PCre to Cre (Fig. 3). Most prominently, Gln to Glu
increased with age in the hippocampus, cortex, and striatum
byþ16 4%,þ10 3%, andþ32 4%, respectively (24 vs. 3 months,
p < 0.05).
3.4. Correlation between neurochemicals
Pearson correlation coefﬁcients (r) were calculated to ﬁnd
probable linear dependences between measured metabolites and/
or metabolite ratios. As depicted in Fig. 4A, besides the obvious
correlation of metabolites and their calculated concentration ratios,
many compounds of the neurochemical proﬁle were signiﬁcantly
correlated. The strongest correlation was found between the two
putative neuronal markers NAA and glutamate (r ¼ 0.821, p < 0.01;
plot in Fig. 4B). Linear ﬁt of glutamate to NAA concentrations across
the brain region, age, and mouse gender, resulted in a signiﬁcant
slope of 1.0  0.1 (F ¼ 170.9, p < 0.0001) and y-intercept of 0.8 
0.6 mmol/g (R2¼ 0.859).While the putative glial markermyo-inositol
and glutamine that is speciﬁcally produced in glial cells by glutamine
synthetase did not generally correlate (r¼0.034, p> 0.05), a linear
relation between glutamine and myo-inositol was speciﬁcally
detected in the cortex (R2 ¼ 0.659; slope of 0.58  0.15 with F ¼
15.47, p < 0.01; y-intercept of 0.25  0.65 mmol/g, Fig. 4C). Among
other signiﬁcant correlations throughout all regions (Fig. 4A), we
found: taurine and choline-containing compounds (r ¼ 0.633, p <
0.01), myo-inositol and total creatine (r ¼ 0.519, p < 0.01), gluta-
mate and aspartate (r ¼ 0.558, p < 0.01). Interestingly, less strong
but signiﬁcant correlations were found between lactate and phys-
iologically important metabolite ratios (Fig. 4D), namely Gln to Glu
(r ¼ 0.311, p < 0.01), Asp to Glu (r ¼ 0.261, p < 0.01), and PCre toCre (r ¼ 0.251, p < 0.01). Linear relations between lactate con-
centration and these metabolite ratios were as follows: Gln to Glu
with slope 7.9  1.4 mmol/g (F ¼ 30.87, p < 0.001) and y ¼ 0.64 
0.52 mmol/g at x ¼ 0 (R2 ¼ 0.524); Asp to Glu with slope 12.0 
2.4 mmol/g (F¼ 24.98, p< 0.001) and y¼ 4.10.4 mmol/g at x¼ 0 of
(R2 ¼ 0.472); PCre to Cre with slope 4.0  1.3 mmol/g (F ¼ 10.01, p
< 0.01) and y ¼ 5.5  1.0 mmol/g at x ¼ 0 of (R2 ¼ 0.263).
3.5. Gender differences
The evolution of the neurochemical proﬁle with age was
dependent on gender, most importantly in taurine, ascorbate, and
total creatine content (p < 0.001, Fig. 5A). A gender effect was also
found for the evolution of glucose (p < 0.05), lactate and alanine (p
< 0.01 for both), as well as for phosphorylethanolamine (p < 0.01)
and aspartate (p < 0.05). Interestingly, because taurine is a sub-
stantially concentrated metabolite in the mouse brain, reaching
concentrations that range between 7 and 15 mmol/g, the simple
combination of taurine content with levels of NAA andmyo-inositol,
allowed to directly separate neurochemical proﬁles by both scanned
brain region and mouse gender (Fig. 5B).
4. Discussion
The present study reports, for the ﬁrst time, longitudinal
neurochemical modiﬁcations in the cortex, hippocampus, and
striatum of the aging mouse, measured noninvasively by high-ﬁeld
1H MRS. The most prominent modiﬁcations were in metabolites
involved in the processes of neurotransmission, energy production,
and membrane lipid metabolism.
Neurotransmitters such as glutamate and GABA decreased dur-
ing aging, suggesting reduction of synaptic function. In line with
this, age-dependent reduction in the density of synaptic proteins
were reported in the rodent brain, namely SNARE complex proteins,
Fig. 5. Three metabolites that occur at relatively high levels in the mouse brain allow differentiating both brain region and mouse gender. (A) Taurine concentration in the cortex and
hippocampus allows distinguishing the mice gender. Indeed, the simultaneous plot of taurine against 2 putative cell-speciﬁc markers, NAA for neurons and myo-inositol for glia,
clearly separates the data in measured region and mouse gender (B). Data from the hippocampus, striatum, and cortex are shown in circles, squares, and triangles, respectively. Data
from male and female mice are shown in blue and red, respectively. (B) Darker colors represent older mice.
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porters, postsynaptic proteins, and components of the synaptic
vesicle cycle (Canas et al., 2009; VanGuilder et al., 2010), which can
contribute to the hippocampal function decline and thus to
reduction of memory performance (Allard et al., 2012; Gage et al.,
1984a; Kennard and Woodruff-Pak, 2011; Pistell et al., 2012).
Because glutamine is exclusively synthesized in glial cells mostly
from synaptic-born glutamate, and then shuttled back to replenish
glutamate neurotransmitter pools in neurons, Gln/Glu may reﬂect
glutamate-glutamine cycle activity between neurons and glial cells.
In line with this, the aging-associated reduction of synaptic con-
nectivity was accompanied by Gln/Glu increase in the cortex,
striatum, and hippocampus. For a long time, noninvasive detection
of a peak corresponding mainly to resonances of both glutamate
and glutamine in the cerebral tissue has been taken as a marker of
function and degeneration in the preclinical and clinical studies. An
independent noninvasive measure of both and also their ratio at
high-magnetic ﬁeld strengthmay provide a more speciﬁc marker to
indicate neuronal function and dysfunction (as glutamate and
glutamine are mostly located in neurons and glia, respectively). For
example, impaired neurotransmission and excitotoxicity after an
ischemic insult lead to transient glutamate decrease and glutamine
accumulation (Berthet et al., 2011; Lei et al., 2009). In line with this
idea, disturbed glutamatergic neurotransmission in schizophrenia
leads to altered levels of glutamine, glutamate, and most notably of
Gln/Glu, as observed in translational and clinical 1H MRS studies
(Bustillo et al., 2009; Duarte et al., 2012b; Hashimoto et al., 2005;
Lutkenhoff et al., 2008; Shirayama et al., 2010; Tayoshi et al., 2009).
In the healthy mouse brain, we observed a tendency (p ¼ 0.076)
for loss of NAA in the hippocampus and striatumwith aging but not
in the cortex, where its concentration was the highest (Fig. 2). NAA
is mainly produced and stored in neurons and shuttled to oligo-
dendrocytes for myelin production, and it has been used as a
marker of neuronal function or density (reviewed in Duarte et al.,
2012a). Similarly, glutamate mainly resides in neurons, being
readily converted to glutamine in glial cells (Gruetter et al., 2003;
McKenna, 2007 and references therein). Accordingly, the results
in Fig. 4 show good correlation between the levels of NAA and
glutamate in the mouse brain in vivo.
In contrast, increased levels of myo-inositol have been taken as
marker of astrogliosis and, in fact, in Alzheimer’s disease, whileNAA loss is frequently associated with neuronal degeneration,
increased levels of myo-inositol are often related to other speciﬁc
markers of astrocyte reactivity (discussed in Duarte et al., 2012a).
This is however debatable and some studies failed to ﬁnd a corre-
lation between pathology-associated astrogliosis and myo-inositol
levels (Duarte et al., 2009; Kim et al., 2005; Kunz et al., 2011). In
addition, glutamine synthetase is speciﬁc to glial cells andwe found
a linear relation between myo-inositol and glutamine concentra-
tions only in the cortex, suggesting that myo-inositol cannot be
taken as a general marker of astrogliosis (Fig. 4C).
The age-dependent modiﬁcations now observed in the mouse
brain resemble those in humans. For example, an elegant study by
Boumezbeur et al., (2010) found a reduction in NAA (10%) and
glutamate (14%) and increase in myo-inositol (þ25%) concentra-
tions in the brain of elderly humans, comparedwith young subjects,
which could result in higher Gln/Glu (Fig. 3). In addition, neuronal
and glial mitochondrial metabolism and glutamate-glutamine cycle
ﬂux was lower in elderly subjects (Boumezbeur et al., 2010).
Glucose transport and consumption vary between brain regions
and they result in lower glucose content in the striatum, compared
with the hippocampus and cortex (reviewed in Barros et al., 2007).
Although regional variation of glucose levels was not found because
isoﬂurane anesthesia alters glucose homeostasis (Duarte and
Gruetter, 2012b), lactate that results from glycolytic metabolism
had distinct levels in the cortex, striatum, and hippocampus.
Furthermore, lactate levels decreased with age, which is in accor-
dance with reduced cerebral glucose utilization upon aging (Gage
et al., 1984b; Tack et al., 1989). This difference in lactate content
may be indicative of the relative rates of cytosolic glycolysis and
mitochondrial oxidative metabolism, further supported by putative
differences in PCre/Cre, which is indicative of adenosine 50-triphos-
phate (ATP) buffering by creatine kinase, and Asp/Glu, which may
indicate integrity of the malate-aspartate shuttle in mitochondria.
Aspartate and glutamate are essential for the transport of reducing
equivalents from cytosol into mitochondria through the malate-
aspartate shuttle to be oxidized in the electron chain and produce
ATP. Asp/Glu was not signiﬁcantly altered by aging but demonstrates
regional differences, that is, it was lower in the striatum compared
with the other regions. This suggests differences in cytosolic pro-
duction of reducing equivalents produced in glycolysis that are then
transferred into the mitochondrial matrix through the malate-
J.M.N. Duarte et al. / Neurobiology of Aging 35 (2014) 1660e16681666aspartate shuttle, a major step in neuroenergetics (Gruetter et al.,
2003; McKenna, 2007). Therefore, measurement of these 2 amino
acids may link excitatory neurotransmission to energy production
and consumption (Duarte et al., 2012a; Kunz et al., 2011).
Lactate levels correlated with Gln/Glu, suggesting that gluta-
mine accumulation in astrocytes, possibly because of increased
glutamate-glutamine cycling, was associated with an increased rate
of glycolysis relative to that of mitochondrial oxidative metabolism,
in accordance to the increased glucose consumption rate with brain
activity (discussed in Duarte and Gruetter, 2012a, 2012b). In line
with this, increased brain activity leads to ammonia accumulation
that requires detoxiﬁcation through glutamine synthesis (discussed
in Merle and Franconi, 2012). A positive association of lactate
concentration with Gln/Glu is in agreement with the proposed
coupling of glial glycolysis and excitatory glutamatergic neuro-
transmission (Pellerin and Magistretti, 2012). In addition, concen-
tration of brain lactate was inversely associated to PCre/Cre and
Asp/Glu, which is explained by higher rate of glycolysis when there
is less storage of high energy phosphates by the buffer system
operated by creatine kinase, that is, less abundance of ATP, and
consequent increased rate of the aspartate aminotransferase that is
essential for the malate-aspartate shuttle.
Compounds involved in membrane metabolism were modiﬁed
with age. In particular, phosphorylethanolamine content was
reduced while tCho increased. Because in the brain choline is
below the NMR detection limit and mainly GPC and PCho
contribute to this intense resonance, the measured choline-
containing compounds are likely reﬂecting membrane lipid syn-
thesis rather than the biosynthesis of the neurotransmitter
acetylcholine (reviewed in Duarte et al., 2012a). During early
development, brain choline increases with age in the mouse cor-
tex (Kulak et al., 2010). The present study shows that this increase
of tCho with age continued through adulthood and aging and that
this increase was not speciﬁc to the cortex. As reviewed in Duarte
et al. (2012a), total choline concentration in the human brain is
positively correlated with age, which has been attributed to
increased release of water-soluble choline-containing compounds
from cell membranes, reﬂecting higher membrane turnover.
Phosphorylethanolamine is a precursor for phosphatidylethanol-
amine, which is a major phospholipid in the brain, and its con-
centration decreases during cerebral development in both rodents
and humans, paralleling the decrease of myelination and cellular
proliferation (Duarte et al., 2012a). Like tCho, phosphor-
ylethanolamine levels continued their developmental trend for
decrease during adulthood and aging. The inverse trajectory in the
evolution of tCho and phosphorylethanolamine levels in the aging
brain may be related to modiﬁcations in cell membrane ﬂuidity
(Calderini et al., 1983). In line with this, a 31P MRS study showed
that the glycerylated forms of such phospholipids increase with
age in the human brain (Blüml et al., 1999).
Frequently, total creatine is used as a reference for the remaining
metabolite concentrations. However, its concentration (signal) was
found to change in certain pathologic conditions (Duarte et al.,
2012b, 2009), during postnatal development (Kulak et al., 2010)
and between gray and white matter (Mukherjee et al., 2000).
Reduction of total creatine concentration with age was observed in
the cortex, hippocampus, and striatum during aging (Fig. 2), sug-
gesting that care should be taken when using creatine as a
normalization factor.
Our previous study on neurochemical modiﬁcations during
early development in the mouse cortex demonstrated a marked
reduction in taurine levels from the age of 10 days to 3 months
(Kulak et al., 2010). Taurine content was not modiﬁed with aging in
the hippocampus or cortex in adult mice. In contrast, it continu-
ously decreased during aging in the striatum, where it is mostconcentrated. Among other functions, taurine is also a neuro-
modulator and interacts with inhibitory GABAA, GABAB, or glycine
receptors thus, displaying capability of modulating synaptic plas-
ticity (reviewed in Albrecht and Schousboe, 2005). This inhibitory
role of taurine is especially important during the period of cortical
synaptogenesis, when brain taurine levels are found to be the
highest (Kulak et al., 2010; Tkác et al., 2003). However, as a small
fraction of taurine is involved in neuromodulation (particularly in
the case of rodents), the main role of taurine may be rather related
to osmoregulation, balancing modiﬁcations in glutamate, gluta-
mine, NAA, and other major neurochemicals during development
(Kulak et al., 2010).
This study was performed in both male and female mice and the
neurochemical proﬁle was similar in both genders. Nevertheless,
some neurochemical differences between genders were identiﬁed
by MANOVA. In particular, taurine concentration that was consis-
tently lower in the cortex and hippocampus of female mice, relative
to age-matched males. In the striatum, this gender-associated dif-
ference in taurine levels was only present in aged mice. Thus,
taurine concentration seems to be related to estrogen activity in the
brain. Indeed, estrogen receptors regulate taurine uptake via the
Naþ-dependent taurine transporter (TauT) in MCF-7 human breast
cancer cells (Han et al., 2006; Shennan and Thomson, 2007). Both
estrogen receptors ERa and ERb are present in the mouse cortex,
hippocampus, and striatum, although striatal levels of either
messenger RNA or protein are much lower (Küppers and Beyer,
1999; Mitra et al., 2003; Shughrue and Merchenthaler, 2000). Es-
trogen receptors modulate brain function and, like taurine, afford
neuroprotection in the cortex and hippocampus (Shughrue and
Merchenthaler, 2000). Although the striatum is not protected by
estrogen after ischemic injury (Shughrue and Merchenthaler,
2000), estrogen receptors afford neuroprotection of striatal dopa-
minergic neurons in animal models of Parkinson’s disease (Al
Sweidi et al., 2012; Campos et al., 2012), possibly by regulating
dopamine transport (Di Liberto et al., 2012) or microgliosis (Liu
et al., 2005).
It should be noted that during early development of the mouse
cortex from P10 to adult age (Kulak et al., 2010), most metabolite
concentrations increased upon tissue differentiation, particularly
glutamate, glutamine, aspartate, NAA, myo-inositol, creatine, and
choline containing compounds. In the present study, while cortical
glutamine and NAA levels were relatively stable (at a 3 and
8.5 mmol/g, respectively), tCho continued increasing, but glutamate,
aspartate, and creatine concentrations decreased during adult age.
Because the juvenile increase in brain metabolite concentrations
appeared asymptotic toward adulthood (Kulak et al., 2010),
different mechanisms must drive metabolic alterations upon aging.
The underlying mechanisms for these alterations remain to be
explored.
In conclusion, the neurochemical proﬁle varies upon healthy
aging in the mouse brain and suggests that aging is associated to
modiﬁcations of energy metabolism, synaptic transmission, and
cell membrane turnover. Furthermore, while NAA and glutamate
may be relevant markers for neuronal density or function, myo-
inositol does not appear to be a general marker for the glial
compartment. This study provided the basal neurochemical proﬁles
of the cortex, hippocampus, and striatum of healthy aging male and
female mice. Because the neurochemical proﬁle is speciﬁc for a
given cerebral status and can also be measured in the human brain,
it serves as a noninvasive biomarker for the detection of neurologic
disorders and for therapy monitoring.
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